title: Exacerbating factors in neuroleptic malignant syndrome: comparisons between cases with death, sequelae, and full recovery.
authors.forename: Masanori
authors.initials: M
authors.lastname: Nagamine
authors.forename: Aihide
authors.initials: A
authors.lastname: Yoshino
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sakurai
authors.forename: Masaki
authors.initials: M
authors.lastname: Sanga
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Takahashi
authors.forename: Soichiro
authors.initials: S
authors.lastname: Nomura
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001831:Body Temperature / Q000187:drug effects; D001971:Bromocriptine / Q000627:therapeutic use; D002423:Cause of Death; D003402:Creatine Kinase / Q000097:blood; D003620:Dantrolene / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D009125:Muscle Relaxants, Central; D001971:Bromocriptine; D003402:Creatine Kinase; D003620:Dantrolene